Abveris Deploys Second Berkeley Lights Beacon® System to Expand Single B Cell Antibody Discovery Capacity
CANTON, Mass., April 22, 2021 – Abveris, Inc.,...
- Therapeutic antibodies against difficult targets such as GPCR, ion channels, glycan targets
- Cell therapies
- Point-of-care diagnostics
- Reagent & anti-idiotypic antibodies supporting clinical trials
- Anywhere else antibodies are needed
Pharma and biotech of various sizes and pipelines rely on Abveris.
Speak with Abveris scientists about how to tackle challenges in antibody discovery.